# Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version

> **NCT02354560** · PHASE4 · UNKNOWN · sponsor: **michal roll** · enrollment: 15 (estimated)

## Conditions studied

- FAP-Familial Adenomatous Polyposis

## Interventions

- **DRUG:** Erythromycin

## Key facts

- **NCT ID:** NCT02354560
- **Lead sponsor:** michal roll
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2015-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354560, "Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02354560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*